Ezzedine Khaled, Parsad Davinder, Harris John E, van Geel Nanja, Gardner Jackie, Bibeau Kristen, Gao Jessy, Ren Haobo, Hamzavi Iltefat H
Department of Dermatology, Henri Mondor University Hospital and Université Paris-Est Créteil Val de Marne, Paris, France.
Department of Dermatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
J Dermatolog Treat. 2025 Dec;36(1):2504082. doi: 10.1080/09546634.2025.2504082. Epub 2025 Jun 4.
Vitiligo often affects quality of life and psychosocial well-being. This analysis of the population-based global Vitiligo and Life Impact Among International Communities (VALIANT) study sought to understand the impact of vitiligo on depression and depressive symptoms from the patient perspective.
The cross-sectional survey collected information on patient demographics, clinical characteristics, mental health diagnoses, and depressive symptoms (assessed using the Patient Health Questionnaire-Depression screener [PHQ-9]) among recruited patients who reported a vitiligo diagnosis.
Of 3541 VALIANT respondents, 24.5% reported formal diagnosis of depression, and 55.0% reported moderate-to-severe symptoms of depression per the PHQ-9. Rates of formally diagnosed depression and moderate-to-severe depressive symptoms were significantly higher in younger patients, those with Fitzpatrick skin types IV-VI (i.e. darker skin), >5% affected body surface area, hand or face involvement, and those receiving mental healthcare versus their counterparts (all < 0.0001). Interestingly, moderate-to-severe depressive symptoms were more common among patients with shorter disease duration (≤2 vs 3-9 and ≥10 years; < 0.01), but there was no correlation between diagnosed depression and disease duration.
These VALIANT study findings highlight that depression may be common but often undiagnosed among patients with vitiligo, reinforcing the importance of an improved and multifaceted approach to vitiligo management.
白癜风常影响生活质量和心理社会幸福感。这项基于人群的全球白癜风与国际社区生活影响（VALIANT）研究的分析旨在从患者角度了解白癜风对抑郁和抑郁症状的影响。
横断面调查收集了招募的自述患有白癜风的患者的人口统计学信息、临床特征、心理健康诊断和抑郁症状（使用患者健康问卷-抑郁筛查量表[PHQ-9]进行评估）。
在3541名VALIANT受访者中，24.5%报告有抑郁症的正式诊断，55.0%根据PHQ-9报告有中度至重度抑郁症状。在年轻患者、皮肤菲茨帕特里克分型为IV-VI型（即肤色较深）、体表面积受累>5%、手部或面部受累以及接受心理保健的患者中，抑郁症正式诊断率和中度至重度抑郁症状发生率显著高于其对应人群（均P<0.0001）。有趣的是，中度至重度抑郁症状在病程较短（≤2年与3-9年及≥10年相比；P<0.01）的患者中更为常见，但抑郁症诊断与病程之间无相关性。
这些VALIANT研究结果突出表明，抑郁症在白癜风患者中可能很常见但往往未被诊断，这强化了采用改进的多方面方法管理白癜风的重要性。
